Middle East respiratory syndrome vaccines

Stanley Perlman; Rahul Vijay

doi:10.1016/j.ijid.2016.04.008

Middle East respiratory syndrome vaccines

Int J Infect Dis. 2016 Jun:47:23-8. doi: 10.1016/j.ijid.2016.04.008. Epub 2016 Apr 7.

Authors

Stanley Perlman¹, Rahul Vijay²

Affiliations

¹ Department of Microbiology, BSB 3-712, University of Iowa, 51 Newton Road, Iowa City, IA 52242, USA. Electronic address: Stanley-perlman@uiowa.edu.
² Department of Microbiology, BSB 3-712, University of Iowa, 51 Newton Road, Iowa City, IA 52242, USA.

Abstract

The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected over 1600 individuals with nearly 600 deaths since it was first identified in human populations in 2012. No antiviral therapies or vaccines are available for its treatment or prophylaxis. Approaches to the development of MERS vaccines are discussed herein, including a summary of previous efforts to develop vaccines useful against human and non-human coronaviruses. A striking feature of MERS is the important role that camels have in transmission. Camel vaccination may be a novel approach to preventing human infection.

Keywords: Coronavirus; Human respiratory disease; Middle East respiratory syndrome; Severe acute respiratory syndrome; Vaccines.

Publication types

Review

MeSH terms

Animals
Camelus
Coronavirus Infections / prevention & control*
Coronavirus Infections / virology
Humans
Middle East Respiratory Syndrome Coronavirus*
Viral Vaccines*

Substances

Viral Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding